Singular Genomics Systems Inc
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. It is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection wit… Read more
Singular Genomics Systems Inc (OMIC) - Net Assets
Latest net assets as of September 2024: $123.25 Million USD
Based on the latest financial reports, Singular Genomics Systems Inc (OMIC) has net assets worth $123.25 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($186.55 Million) and total liabilities ($63.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $123.25 Million |
| % of Total Assets | 66.07% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.34 |
Singular Genomics Systems Inc - Net Assets Trend (2019–2023)
This chart illustrates how Singular Genomics Systems Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Singular Genomics Systems Inc (2019–2023)
The table below shows the annual net assets of Singular Genomics Systems Inc from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $179.01 Million | -31.24% |
| 2022-12-31 | $260.32 Million | -22.56% |
| 2021-12-31 | $336.17 Million | +752.07% |
| 2020-12-31 | $-51.55 Million | -108.51% |
| 2019-12-31 | $-24.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Singular Genomics Systems Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31241500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $155.00K | 0.09% |
| Other Components | $516.44 Million | 288.50% |
| Total Equity | $179.01 Million | 100.00% |
Singular Genomics Systems Inc Competitors by Market Cap
The table below lists competitors of Singular Genomics Systems Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NexMetals Mining Corp. Common Shares
NASDAQ:NEXM
|
$36.82 Million |
|
Ramssol Group Bhd
KLSE:0236
|
$36.83 Million |
|
EMBARK EDUCATION LTD.
F:9EV
|
$36.84 Million |
|
Young Shine Electric Co., Ltd.
TWO:2249
|
$36.85 Million |
|
Fortune Rise Acquisition Corp
NASDAQ:FRLA
|
$36.81 Million |
|
Capital & Regional Plc
PINK:CRPLF
|
$36.81 Million |
|
Vietnam Tanker JSC
VN:VTO
|
$36.81 Million |
|
PharmAust Ltd
F:ECQ
|
$36.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Singular Genomics Systems Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 260,321,000 to 179,006,000, a change of -81,315,000 (-31.2%).
- Net loss of 94,820,000 reduced equity.
- Share repurchases of 19,000 reduced equity.
- Other comprehensive income increased equity by 992,000.
- Other factors increased equity by 12,532,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-94.82 Million | -52.97% |
| Share Repurchases | $19.00K | -0.01% |
| Other Comprehensive Income | $992.00K | +0.55% |
| Other Changes | $12.53 Million | +7.0% |
| Total Change | $- | -31.24% |
Book Value vs Market Value Analysis
This analysis compares Singular Genomics Systems Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.36 | $20.01 | x |
| 2020-12-31 | $-22.31 | $20.01 | x |
| 2021-12-31 | $139.23 | $20.01 | x |
| 2022-12-31 | $109.77 | $20.01 | x |
| 2023-12-31 | $73.77 | $20.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Singular Genomics Systems Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3257.30%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.48x
- Recent ROE (-52.97%) is below the historical average (-23.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.87 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.51 Million |
| 2021 | -29.42% | 0.00% | 0.00x | 1.06x | $-132.51 Million |
| 2022 | -33.91% | -11538.69% | 0.00x | 1.26x | $-114.30 Million |
| 2023 | -52.97% | -3257.30% | 0.01x | 1.48x | $-112.72 Million |
Industry Comparison
This section compares Singular Genomics Systems Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $771,083,081
- Average return on equity (ROE) among peers: -146.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Singular Genomics Systems Inc (OMIC) | $123.25 Million | 0.00% | 0.51x | $36.81 Million |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $520.03 Million | 8.62% | 0.25x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $2.56 Billion | 36.42% | 1.05x | $36.83 Billion |
| Align Technology Inc (ALGN) | $161.15 Million | 22.17% | 0.38x | $11.50 Billion |
| AngioDynamics Inc (ANGO) | $372.19 Million | 2.67% | 0.10x | $344.14 Million |
| Ansell Limited (ANSLF) | $1.56 Billion | 10.20% | 0.61x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $7.93 Billion |
| AtriCure Inc (ATRC) | $483.76 Million | 10.38% | 0.27x | $1.38 Billion |
| Avinger Inc (AVGR) | $4.24 Million | -1323.46% | 11.63x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $18.90 Million | -243.53% | 0.62x | $156.14 Million |